Diabetic Ketoacidosis Associated With Second Generation Antipsychotics: A Case Study and Review of Literature

키워드

참고문헌 (54)

1. Zhang JP, "Efficacy and safety of individual second-generation vs. first-gener ation antipsychotics in first-episode psychosis : a systematic review and meta-analysis", Int J Neuropsychopharmacol, 16, pp.1205~1218 (2013)
2. Arana GW, "An overview of side effects caused by typical antipsychotics", J Clin Psychiatry, 61(Suppl 8), pp.5~13 (2000)
3. Correll CU, "From receptor pharmacology to improved outcomes: indi vidualising the selection, dosing, and switching of antipsychotics", Eur Psychiatry, 25(Suppl 2), pp.S12~S21 (2010)
4. El-Mallakh P, "Strategies to improve medication adherence in patients with schizophrenia : the role of support services", Neuropsychiatric Dis Treat, 11, pp.1077~1090 (2015)
5. Reist C, "Second generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia : an observational pharmacoepidemiology study from 1988 to 2002", J Clin Psychopharmacol, 27, pp.46~51 (2007)
6. Lipscombe LL, "Antipsychotic drugs and hyperglycemia in older patients with diabetes", Arch Intern Med, 169, pp.1282~1289 (2009)
7. Koller E, "Clozapine-associated diabetes", Am J Med, 111, pp.716~723 (2001)
8. Koller EA, "A survey of re ports of quetiapine-associated hyperglycemia and diabetes mellitus", J Clin Psychiatry, 65, pp.857~863 (2004)
9. Stubbs B, "The prevalence and predictors of type two diabetes mellitus in people with schizophrenia : a systematic review and comparative meta-analysis", Acta Psychiatr Scand, 132, pp.144~157 (2015)
10. Grajales D, "Second-generation antipsychot ics and dysregulation of glucose metabolism : beyond weight gain", Cells, 8, pp.1336~ (2019)
11. Brown S, "Twenty-five year mortality of a community cohort with schizophrenia", Br J Psychiatry, 196, pp.116121~ (2010)
12. Kahn SE, "Pathophysiology and treatment of type 2 diabetes : perspectives on the past, present, and future", Lancet, 383, pp.1068~1083 (2014)
13. Vancampfort D, "Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder : a systematic review and meta-analysis", World Psychiatry, 14, pp.339~347 (2015)
14. Fayfman M, "Management of hyperglyce mic crises : diabetic ketoacidosis and hyperglycemic hyperosmolar state", Med Clin North Am, 101, pp.587~606 (2017)
15. Lipscombe LL, "Atypical antipsychotics and hyperglycemic emergen cies : multicentre, retrospective cohort study of administrative data", Schizophr Res, 154, pp.54~60 (2014)
16. Umpierrez GE, "Diabetic ketoacidosis : risk factors and management strategies", Treat Endocrinol, 2, pp.95~108 (2003)
17. Vuk A, "Diabetic ketoacidosis associated with antipsychotic drugs : case reports and a review of litera ture", Psychiatr Danub, 29, pp.121~135 (2017)
18. Jin H, "Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics : an analysis of 45 published cases", Ann Clin Psy chiatry, 14, pp.59~64 (2002)
19. Wilson DR, "New-on set diabetes and ketoacidosis with atypical antipsychotics", Schizophr Res, 59, pp.1~6 (2003)
20. Smith RC, "Clozapine, risperidone, olanzapine, and conven tional antipsychotic drug effects on glucose, lipids, and leptin in schizo phrenic patients", Int J Neuropsychopharmacol, 8, pp.183~194 (2005)
21. English P, "Hyperglycaemic crises and lactic acidosis in di abetes mellitus", Postgrad Med J, 80, pp.253~261 (2004)
22. Mir S, "Atypical antipsychotics and hyperglycaemia", Int Clin Psychopharmacol, 16, pp.63~73 (2001)
23. Abidi S, "From chlorpromazine to clozapine—antipsy chotic adverse effects and the clinician’s dilemma", Can J Psychiatry, 48, pp.749~755 (2003)
24. Memarzia J, "The use of antipsychotics in preschool ers : a veto or a sensible last option?", J Psychopharmacol, 28, pp.303319~ (2014)
25. Barski L, "Comparison of diabetic ketoacidosis in patients with type-1 and type 2 diabetes mellitus", Am J Med Sci, 345, pp.326~330 (2013)
26. Poitout V, "Glucolipotoxicity of the pancreatic beta cell", Biochim Biophys Acta, 1801, pp.289~298 (2010)
27. Alghamdi F, "A novel insulin receptor-signaling platform and its link to in sulin resistance and type 2 diabetes", Cell Signal, 26, pp.1355~1368 (2014)
28. Ren L, "The IRS", PI3K, Life Sci, pp.2019, 217[DOI]
29. Mondelli V, "Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways", Transl Psychiatry, 3, pp.e208~ (2013)
30. Shamshoum H, "Peripheral mechanisms of acute olanzapine induced metabolic dysfunction : a review of in vivo models and treatment approaches", Behav Brain Res, 400, pp.113049~ (2021)
31. Liu X, "Time-dependent changes and potential mechanisms of glucose-lipid metabolic disor ders associated with chronic clozapine or olanzapine treatment in rats", Sci Rep, 7, pp.2762~ (2017)
32. Engl J, "Olanzapine impairs glycogen synthesis and insulin sig naling in L6 skeletal muscle cells", Mol Psychiatry, 10, pp.1089~1096 (2005)
33. Panariello F, "Clozapine impairs insulin action by up-regulating Akt phosphor ylation and Ped", Pea-15 protein abundance, 2012, pp.227, 1485~1492
34. Rubí B, "Dopamine D2-like receptors are expressed in pancre atic beta cells and mediate inhibition of insulin secretion", J Biol Chem, 280, pp.36824~36832 (2005)
35. Simpson N, "Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro", Mol Endocrinol, 26, pp.1757~1772 (2012)
36. oscillations, "Mol Endocrinol", 2012, 1928~1940
37. Cataldo Bascuñan LR, "Serotoner gic regulation of insulin secretion", Acta Physiol(Oxf), 225, pp.e13101~ (2019)
38. Bennet H, "Serotonin(5-HT)receptor 2b activation augments glucose-stimu lated insulin secretion in human and mouse islets of Langerhans", Diabetologia, 59, pp.744~754 (2016)
39. Weston-Green K, "Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels", Eur Neuropsychopharmacol, 22, pp.364~373 (2012)
40. Smith GC, "Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat", Diabetologia, 51, pp.2309~2317 (2008)
41. Nagata M, "Clozap ine-induced acute hyperglycemia is accompanied with elevated serum concentrations of adrenaline and glucagon in rats", Biol Pharm Bull, 41, pp.1286~1290 (2018)
42. Smith GC, "Clozapine and que tiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats : implications for glucose metabolism and food choice behaviour", Schizophr Res, 115, pp.30~40 (2009)
43. Castellani LN, "Glucagon receptor knockout mice are protected against acute olan zapine-induced hyperglycemia", Psychoneuroendocrinology, 82, pp.38~45 (2017)
44. Holst JJ, "The incretin system and its role in type 2 diabetes mellitus", Mol Cell Endocrinol, 297, pp.127~136 (2009)
45. Polcwiartek C, "Diabetic ketoacidosis and diabetes associated with antipsychotic expo sure among a previously diabetes-naive population with schizophre nia : a nationwide nested case–control study", Diabetologia, 60, pp.16781690~ (2017)
46. Ramaswamy K, "Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine", Drug Saf, 30, pp.589~599 (2007)
47. Guenette MD, "Atypical an tipsychotics and diabetic ketoacidosis : a review", Psychopharmacology(Berl), 226, pp.1~12 (2013)
48. Leslie DL, "Incidence of newly diagnosed diabetes at tributable to atypical antipsychotic medications", Am J Psychiatry, 161, pp.1709~1711 (2004)
49. Cohen D, "Second-generation antipsychotic-associated di abetes mellitus and diabetic ketoacidosis : mechanisms, predictors, and screening need", J Clin Psychiatry, 70, pp.765~766 (2009)
50. Henderson DC, "Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics", J Clin Psychiatry, 68, pp.533~541 (2007)
51. Polcwiartek C, "Diabetic ketoacidosis in patients exposed to antipsychotics : a sys tematic literature review and analysis of Danish adverse drug event re ports", Psychopharmacology(Berl), 233, pp.3663~3672 (2016)
52. Kim HH, "Two cases of diabetic ketoacidosis associated with paliperidone treatment in schizophrenia", J Korean Diabetes, 15, pp.178~184 (2014)
53. Ely SF, "Fatal diabetic ketoacidosis and antipsychot ic medication", J Forensic Sci, 58, pp.398~403 (2013)
54. Lee JS, "Korean Medi cation Algorithm for Schizophrenia 2019, second revision : treatment of psychotic symptoms", Clin Psychopharmacol Neurosci, 18, pp.386~386394 (2020)

관련 논문AI추천